Rifabutin labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Rifabutin }} | {{Rifabutin}} | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
Labels | ==Labels and Packages== | ||
PRINCIPAL DISPLAY PANEL - 150 mg Capsule Label | PRINCIPAL DISPLAY PANEL - 150 mg Capsule Label | ||
| Line 27: | Line 27: | ||
|- | |- | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 03:24, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Labels and Packages
PRINCIPAL DISPLAY PANEL - 150 mg Capsule Label
NDC 0013-5301-17
100 Capsules Rx only
Mycobutin® rifabutin capsules, USP
150 mg
Pfizer Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, NY, NY 10017[1]
 |
References
- ↑ "MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.